Conflict of interest: No conflict of interest for any of the authors.
Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes
Version of Record online: 16 MAY 2014
© 2014 Wiley Periodicals, Inc.
American Journal of Hematology
Volume 89, Issue 8, pages 809–812, August 2014
How to Cite
Komrokji, R. S., Padron, E., Yu, D., Fulp, W. J., Rodriguez, Y., Tinsley, S., List, A. F. and Lancet, J. E. (2014), Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes. Am. J. Hematol., 89: 809–812. doi: 10.1002/ajh.23749
Data presented at American Society of Hematology (ASH) 2011 Meeting, abstract # 1714.
- Issue online: 14 JUL 2014
- Version of Record online: 16 MAY 2014
- Accepted manuscript online: 24 APR 2014 10:34PM EST
- Manuscript Accepted: 21 APR 2014
- Manuscript Received: 17 APR 2014
- Genentech Inc.
Additional Supporting Information may be found in the online version of this article.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.